Trials / Unknown
UnknownNCT03402165
Serum Alpha-fetoprotein Levels and Response to Direct Antiviral Therapy in Patients With Chronic Hepatitis C
Impact of Serum Alpha-fetoprotein Levels on the Response to Direct Antiviral Therapy in Egyptian Patients With Chronic Hepatitis C
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 1,200 (estimated)
- Sponsor
- Sherief Abd-Elsalam · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Alpha-fetoprotein Levels on the Response to direct Antiviral Therapy in Patients with Chronic Hepatitis C
Detailed description
Impact of Serum Alpha-fetoprotein Levels on the Response to direct Antiviral Therapy in Egyptian Patients with Chronic Hepatitis C
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sofosbuvir and Ledipasvir or sofosbuvir and daklatasuvir | Response to DAAD's and developing HCC |
Timeline
- Start date
- 2017-01-01
- Primary completion
- 2022-12-01
- Completion
- 2022-12-30
- First posted
- 2018-01-18
- Last updated
- 2018-08-27
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT03402165. Inclusion in this directory is not an endorsement.